BioSpace News Archive

Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII) announced today that it has completed a minority investment and entered into an acquisition option agreement with CarePICS, LLC (CarePICS ® ), a telehealth company offering a virtual care platform designed to improve the outcomes of patients suffering from peripheral artery disease (PAD), critical limb ischemia (CLI) and lower extremity wounds.

Trial did not meet the co-primary efficacy endpoints; no new safety signals identified

License and Commercialization Agreement Executed with Pierre Fabre to Develop and Commercialize a Potential Best-in-Class Antibody Therapy, VB421, for the Treatment of Thyroid Eye Disease IND Accepted for Lead Program, VB119, for the Treatment of Membranous Nephropathy

Olympus announced its support of The Joint Commission’s recommended safety actions for managing the hazards of exposure to surgical smoke for healthcare staff in operating rooms.

Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 20 th Annual Needham Virtual Healthcare Conference on Thursday, April 15, at 3:00 p.m. ET.

Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the successful completion of its long-term research project with Professor Dr. Feral Temelli at the University of Alberta (UofA)

The rising popularity of outsourcing implementations across the healthcare industry due to the benefits such as affordability and less-time consumption will serve as a vital growth prospect for the pharmaceutical contract development and manufacturing market during the forecast period of 2020-2030.

Evrysdi (risdiplam) 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy (SMA)

ViaDerma, Inc., is pleased to provide an update of estimated sales and revenue numbers for the first quarter of 2021, as well as additional highlights of the Company’s year to date progress.

The shareholders of Mentice AB, reg. no. 566556-4241, are hereby given notice to attend the annual shareholders’ meeting to be held on 6 May 2021 by completing a form for postal voting.